5/3
11:53 am
mrk
Here's Why Merck (MRK) is a Strong Momentum Stock [Yahoo! Finance]
Low
Report
Here's Why Merck (MRK) is a Strong Momentum Stock [Yahoo! Finance]
5/3
11:06 am
mrk
Generic Sterile Injectable Market Size to Worth USD 108.54 Bn by 2033 [Yahoo! Finance]
Low
Report
Generic Sterile Injectable Market Size to Worth USD 108.54 Bn by 2033 [Yahoo! Finance]
5/2
04:13 pm
mrk
4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration [Yahoo! Finance]
Low
Report
4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration [Yahoo! Finance]
5/2
05:19 am
mrk
Merck reports data from Phase III gastric cancer treatment trial [Yahoo! Finance]
Low
Report
Merck reports data from Phase III gastric cancer treatment trial [Yahoo! Finance]
5/2
03:58 am
mrk
The top pharmaceutical companies by R&D expenditure [Yahoo! Finance]
Low
Report
The top pharmaceutical companies by R&D expenditure [Yahoo! Finance]
5/1
07:00 pm
mrk
15 Best Places to Retire in Florida That You've Never Heard Of [Yahoo! Finance Canada]
Low
Report
15 Best Places to Retire in Florida That You've Never Heard Of [Yahoo! Finance Canada]
5/1
06:59 pm
mrk
15 Best Places to Retire in Florida That You've Never Heard Of [Yahoo! Finance]
Low
Report
15 Best Places to Retire in Florida That You've Never Heard Of [Yahoo! Finance]
5/1
05:06 pm
mrk
HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC [Yahoo! Finance]
Low
Report
HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC [Yahoo! Finance]
4/25/2024
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
2.5%
merck & company, inc. (new)
2/1/2024
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
4.7%
merck & company, inc. (new)
10/26/2023
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
1.5%
merck & company, inc. (new)
8/1/2023
06:30 am
mrk
merck & company, inc. (new)
MISS
Report
-1.3%
merck & company, inc. (new)
5/3
04:11 pm
mrk
Form 10-Q Merck & Co., Inc. For: Mar 31
Low
Report
Form 10-Q Merck & Co., Inc. For: Mar 31
5/2
04:30 pm
mrk
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Romanelli Joseph
Low
Report
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Romanelli Joseph
5/2
04:26 pm
mrk
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Larson Betty D
Low
Report
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Larson Betty D
5/2
04:24 pm
mrk
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Smart Dalton
Low
Report
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Smart Dalton
5/2
04:22 pm
mrk
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Guindo Chirfi
Low
Report
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Guindo Chirfi
5/2
04:21 pm
mrk
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Downing Cristal N
Low
Report
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Downing Cristal N
5/2
04:19 pm
mrk
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Zachary Jennifer
Low
Report
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Zachary Jennifer
5/2
04:18 pm
mrk
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Li Dean Y
Low
Report
Form 4 Merck & Co., Inc. For: Apr 30 Filed by: Li Dean Y
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
3/28
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
7.5%
3/25
Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
6.5%
3/3
Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael
6.1%
3/2
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
5.6%
3/17
Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
5.3%
4/1
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
4.2%
4/27
UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters]
3.4%
10/28
Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters]
3.3%
10/3
Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily]
2.7%
1/31
Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters]
2.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register